Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Patent expiry trametinib?
Are there income restrictions for lipitor's patient program?
Lipitor vs generics what's the price gap?
Mebendazole for kids price?
How does iron rich food intake impact lipitor's efficacy?

Xarelto sales in pad?

See the DrugPatentWatch profile for Xarelto

What were Xarelto (rivaroxaban) sales in PAD, and what does “PAD” mean here?

“PAD” can mean different things in searches:
- Peripheral Artery Disease (the most common medical meaning)
- A specific market/region abbreviation (less likely without more context)
- A company’s sales segment or shorthand used in a report

With only the query provided (“Xarelto sales in pad”), there isn’t enough information to identify the exact geography/segment or the specific dataset you’re referring to.

If you mean Peripheral Artery Disease: how is Xarelto positioned and sold for PAD?

For PAD (Peripheral Artery Disease), Xarelto is used for vascular protection strategies that depend on patient risk and the approved indication(s) in a given country. Sales for “PAD” in any year usually come from:
- Label/indication mapping (sales attributed to patients treated for PAD-related indications)
- Payer/claims segmentation (claims tagged as PAD)
- Manufacturer reporting that may not isolate PAD sales cleanly

What figures can you expect to find?

Depending on the source, “Xarelto sales in PAD” could appear as:
- Sub-indication sales (PAD only) in regulatory/earnings materials (rare and usually country-specific)
- Sales by geography, where PAD is inferred from prescribing/claims data (more common in market research)
- Market research estimates using epidemiology + treatment penetration (not the same as company-reported sales)

What I need from you to answer with exact numbers

Reply with any one of the following and I can narrow to the right sales figure:
1) Which “PAD” you mean (Peripheral Artery Disease vs a region or report segment)
2) Country/region (e.g., US, EU5, UK, Japan, “global”)
3) Time period (e.g., 2023, Q1 2024, trailing 12 months)
4) Source type you’re looking for (e.g., company earnings, IQVIA/claims data, prescriptions, or market research)

If you confirm “PAD = Peripheral Artery Disease” and the geography + year, I’ll format the answer around the most relevant sales metric available for that context.

Sources

No sources were provided in the prompt, so no claims with citations are possible yet.



Other Questions About Xarelto :

Fda monograph xarelto tab 20mg? Cost of xarelto on medicare? Xarelto generic names? Who invented xarelto? Xarelto patent expiry bayer? Cheapest price for xarelto 20 mg? Does xarelto lose patent in march 2025?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Fully Aligned

Patient Risk: Low

Summary

The AI-generated warning/claim is directly supported by XARELTO’s FDA Boxed Warning and corresponding Warnings sections (5.1 and 5.3) with no contradictions or material omissions identified for the stated claim.

Category Scores

Warnings
100
Excellent

Accurate Statements

Premature discontinuation of XARELTO increases the risk of thrombotic events.
BOXED WARNING (A); Warnings and Precautions (5.1) states premature discontinuation of any oral anticoagulant, including XARELTO, without adequate alternative anticoagulation increases thrombotic events.
Spinal/epidural hematoma can occur in patients undergoing neuraxial anesthesia or spinal puncture while treated with XARELTO.
BOXED WARNING (B); Warnings and Precautions (5.3) states patients treated with anticoagulant agents for prevention of thromboembolic complications are at risk of epidural/spinal hematoma when neuraxial anesthesia or spinal puncture is employed.

Unsupported Statements

Contradictions

Important Omissions

Safety Assessment

Potential Patient Risk: Low
The statements evaluated are safety-relevant but are explicitly supported by the Boxed Warning and corresponding warning sections; no missing or incorrect critical elements were identified relative to the narrow claim.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Fully Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
32
Visibility
26
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

Xarelto (rivaroxaban)

Core Claims
  • Xarelto (rivaroxaban) is used for PAD (Peripheral Artery Disease) vascular protection strategies.
  • Sales for PAD in any year usually come from label/indication mapping, payer/claims segmentation, or manufacturer reporting that may not isolate PAD sales cleanly.
  • Xarelto sales in PAD could appear as sub-indication sales, sales by geography (PAD inferred), or market research estimates using epidemiology plus treatment penetration.
Differentiators
  • Positioned based on patient risk and approved indication(s) in a given country.
  • Sales attribution may rely on mapping/segmentation methods rather than clean manufacturer isolation.
  • PAD figures depend on how geography and time period are defined.
Pricing Perception: Not Mentioned